In the rapidly evolving pharmaceutical manufacturing landscape, the integration of 3D printing technology presents a groundbreaking approach to enhance efficacy and flexibility for the development of drug delivery systems.
By seamlessly merging Aprecia's commercial-scale 3D printing platform with our cutting-edge solubility enhancement technology based on Parteck® SLC silica carrier, we are redefining manufacturing possibilities. This can be achieved through either pre-loaded carrier materials or direct integration of the silica carrier during the 3D printing process, paving the way for a new era in pharmaceutical manufacturing.
Speakers
Thomas Kipping, Ph.D.
Merck
Head of Drug Carriers
Dr. Thomas Kipping is an expert in the field of pharmaceutical technology and formulation development. Thomas is currently the head of drug carriers at Merck. With more than 10 years of industrial experience, spanning various sectors within the pharmaceutical industry, including drug product development and CDMO services, he has consistently demonstrated a strong commitment to advancing pharmaceutical sciences and enhancing drug development processes He holds a Ph.D. in pharmaceutical technology from the University of Bonn.
Michelle Schilling, Ph.D.
Aprecia Pharmaceuticals
Product Development Manager
Dr. Schilling is currently the manager of product development at Aprecia Pharmaceuticals with 14 years of pharmaceutical experience. She has been a technical leader on multiple cross-functional product development teams with expertise in formulation and process design from early development through scale-up of IR and modified-release drug products.
Her experience includes process development with 3-D printing (binder jetting), tableting, fluid-bed manufacturing, high-shear granulation, coacervation, encapsulation, and roller compaction. Michelle is a chemist by training and holds a Ph.D. in industrial and physical pharmacy from Purdue University.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
Duration:1h
Language:English
Session 1:presented April 24, 2025
To continue reading please sign in or create an account.
Don't Have An Account?